Nestlé, the world’s largest packaged food company, has introduced a new protein shot designed to help individuals manage hunger while working toward weight loss. The move comes as consumer demand for weight-loss products grows, fueled by the increasing popularity of GLP-1 medications like Ozempic and Wegovy.
The new product, Boost Pre-Meal Hunger Support, is intended to be taken 10 to 30 minutes before meals. Each 4.2-ounce shot contains 10 grams of protein and only 45 calories, according to the company’s website. A four-pack of shots is priced at $10.99 and is currently available for purchase on Amazon and at select CVS stores.
Stefan Palzer, Nestlé’s Chief Technology Officer, explained to Reuters that the product works by boosting natural GLP-1 levels, a hormone that helps regulate blood sugar and suppress appetite. “This dose has a significant effect on satiety,” he said, referring to the product’s ability to reduce hunger.
GLP-1 is a hormone produced in the gut that plays a key role in managing hunger. Weight-loss drugs such as Ozempic, Wegovy, and Zepbound function by mimicking the effects of this hormone.
Morgan Stanley analysts predict that the global market for GLP-1-based weight-loss treatments will reach $105 billion by 2030. The firm also expects that by 2035, around 31.5 million people in the U.S. — nearly 9% of the population — will be using these treatments.
Nestlé’s protein shot is the latest addition to its growing portfolio of products aimed at consumers seeking weight loss solutions. Earlier this year, the company launched a line of frozen meals called Vital Pursuit, which is tailored for GLP-1 users. The line features high-protein, low-calorie options like pizzas, sandwiches, pastas, and bowls.
Mark Schneider, the former CEO of Nestlé, noted in May that the surge in weight-loss drug use has shifted consumers’ nutritional needs, creating new opportunities for food companies to innovate in this space.
